Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus platinum and nab-paclitaxel as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2100047437Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, cisplatin, carboplatin and paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Beijing Tongren Hospital. Primary endpoints: Pathological complete response of primary tumor and regional lymph nodes and Combined positive score. Started Jun 2021; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100047437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047437.